Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF)

Alan W. Spannagel, Joseph R. Reeve, George H. Greeley, Noboro Yanaihara, Rodger A. Liddle, Gary M. Green

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    A luminal cholecystokinin releasing factor (LCRF), has been purified from intestinal secretion and found to have a mass of 8136 daltons. The amino-terminal 41 residues have been sequenced. Previous studies showed that intraduodenal infusion of the synthetic amino-terminal 35 amino acid peptide, LCRF1-35 significantly stimulated pancreatic protein and fluid secretion in conscious rats, but the peptide did not stimulate amylase release from isolated, dispersed pancreatic acini. In the present study, several fragments of LCRF were synthesized and tested for CCK-releasing activity (pancreatic protein secretion) to determine whether shorter fragments of LCRF exhibit the characteristic biological activity of native LCRF and synthetic LCRF1-35. Compounds tested were LCRF1-41, LCRF1-35, LCRF1-6, and LCRF11-25. Of the fragments shorter than LCRF1-35, only LCRF11-25 but not LCRF1-6 had significant CCK releasing activity. LCRF1-41 was equivalent to LCRF1-35 in potency and efficacy. Intravenous and intraduodenal infusion of LCRF1-35 elicited nearly identical dose-response curves. Copyright (C) 1998 Elsevier Science B.V.

    Original languageEnglish (US)
    Pages (from-to)161-164
    Number of pages4
    JournalRegulatory Peptides
    Volume73
    Issue number3
    DOIs
    StatePublished - Feb 27 1998

    Fingerprint

    Cholecystokinin
    Bioactivity
    Intestinal Secretions
    Fluids and Secretions
    Peptides
    Amylases
    Intravenous Infusions
    Rats
    Proteins
    Amino Acids
    Fluids

    Keywords

    • CCK
    • Exocrine pancreas
    • Feedback regulation

    ASJC Scopus subject areas

    • Biochemistry
    • Endocrinology
    • Physiology
    • Neuroscience(all)

    Cite this

    Spannagel, A. W., Reeve, J. R., Greeley, G. H., Yanaihara, N., Liddle, R. A., & Green, G. M. (1998). Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF). Regulatory Peptides, 73(3), 161-164. https://doi.org/10.1016/S0167-0115(97)01074-4

    Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF). / Spannagel, Alan W.; Reeve, Joseph R.; Greeley, George H.; Yanaihara, Noboro; Liddle, Rodger A.; Green, Gary M.

    In: Regulatory Peptides, Vol. 73, No. 3, 27.02.1998, p. 161-164.

    Research output: Contribution to journalArticle

    Spannagel, Alan W. ; Reeve, Joseph R. ; Greeley, George H. ; Yanaihara, Noboro ; Liddle, Rodger A. ; Green, Gary M. / Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF). In: Regulatory Peptides. 1998 ; Vol. 73, No. 3. pp. 161-164.
    @article{29a4736bce11470dabc4e06d3feb7fe2,
    title = "Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF)",
    abstract = "A luminal cholecystokinin releasing factor (LCRF), has been purified from intestinal secretion and found to have a mass of 8136 daltons. The amino-terminal 41 residues have been sequenced. Previous studies showed that intraduodenal infusion of the synthetic amino-terminal 35 amino acid peptide, LCRF1-35 significantly stimulated pancreatic protein and fluid secretion in conscious rats, but the peptide did not stimulate amylase release from isolated, dispersed pancreatic acini. In the present study, several fragments of LCRF were synthesized and tested for CCK-releasing activity (pancreatic protein secretion) to determine whether shorter fragments of LCRF exhibit the characteristic biological activity of native LCRF and synthetic LCRF1-35. Compounds tested were LCRF1-41, LCRF1-35, LCRF1-6, and LCRF11-25. Of the fragments shorter than LCRF1-35, only LCRF11-25 but not LCRF1-6 had significant CCK releasing activity. LCRF1-41 was equivalent to LCRF1-35 in potency and efficacy. Intravenous and intraduodenal infusion of LCRF1-35 elicited nearly identical dose-response curves. Copyright (C) 1998 Elsevier Science B.V.",
    keywords = "CCK, Exocrine pancreas, Feedback regulation",
    author = "Spannagel, {Alan W.} and Reeve, {Joseph R.} and Greeley, {George H.} and Noboro Yanaihara and Liddle, {Rodger A.} and Green, {Gary M.}",
    year = "1998",
    month = "2",
    day = "27",
    doi = "10.1016/S0167-0115(97)01074-4",
    language = "English (US)",
    volume = "73",
    pages = "161--164",
    journal = "Regulatory Peptides",
    issn = "0167-0115",
    publisher = "Elsevier",
    number = "3",

    }

    TY - JOUR

    T1 - Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF)

    AU - Spannagel, Alan W.

    AU - Reeve, Joseph R.

    AU - Greeley, George H.

    AU - Yanaihara, Noboro

    AU - Liddle, Rodger A.

    AU - Green, Gary M.

    PY - 1998/2/27

    Y1 - 1998/2/27

    N2 - A luminal cholecystokinin releasing factor (LCRF), has been purified from intestinal secretion and found to have a mass of 8136 daltons. The amino-terminal 41 residues have been sequenced. Previous studies showed that intraduodenal infusion of the synthetic amino-terminal 35 amino acid peptide, LCRF1-35 significantly stimulated pancreatic protein and fluid secretion in conscious rats, but the peptide did not stimulate amylase release from isolated, dispersed pancreatic acini. In the present study, several fragments of LCRF were synthesized and tested for CCK-releasing activity (pancreatic protein secretion) to determine whether shorter fragments of LCRF exhibit the characteristic biological activity of native LCRF and synthetic LCRF1-35. Compounds tested were LCRF1-41, LCRF1-35, LCRF1-6, and LCRF11-25. Of the fragments shorter than LCRF1-35, only LCRF11-25 but not LCRF1-6 had significant CCK releasing activity. LCRF1-41 was equivalent to LCRF1-35 in potency and efficacy. Intravenous and intraduodenal infusion of LCRF1-35 elicited nearly identical dose-response curves. Copyright (C) 1998 Elsevier Science B.V.

    AB - A luminal cholecystokinin releasing factor (LCRF), has been purified from intestinal secretion and found to have a mass of 8136 daltons. The amino-terminal 41 residues have been sequenced. Previous studies showed that intraduodenal infusion of the synthetic amino-terminal 35 amino acid peptide, LCRF1-35 significantly stimulated pancreatic protein and fluid secretion in conscious rats, but the peptide did not stimulate amylase release from isolated, dispersed pancreatic acini. In the present study, several fragments of LCRF were synthesized and tested for CCK-releasing activity (pancreatic protein secretion) to determine whether shorter fragments of LCRF exhibit the characteristic biological activity of native LCRF and synthetic LCRF1-35. Compounds tested were LCRF1-41, LCRF1-35, LCRF1-6, and LCRF11-25. Of the fragments shorter than LCRF1-35, only LCRF11-25 but not LCRF1-6 had significant CCK releasing activity. LCRF1-41 was equivalent to LCRF1-35 in potency and efficacy. Intravenous and intraduodenal infusion of LCRF1-35 elicited nearly identical dose-response curves. Copyright (C) 1998 Elsevier Science B.V.

    KW - CCK

    KW - Exocrine pancreas

    KW - Feedback regulation

    UR - http://www.scopus.com/inward/record.url?scp=0032570850&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0032570850&partnerID=8YFLogxK

    U2 - 10.1016/S0167-0115(97)01074-4

    DO - 10.1016/S0167-0115(97)01074-4

    M3 - Article

    VL - 73

    SP - 161

    EP - 164

    JO - Regulatory Peptides

    JF - Regulatory Peptides

    SN - 0167-0115

    IS - 3

    ER -